Stocks · Health care · Biological Products, (No Diagnostic Substances)

Gilead Sciences

GILD Clue Score57

United States Fiscal year ends December CIK 0000882095 Results filed 29 Oct 2026

Add to watchlist

What the insiders did Mostly scheduled

By person

35 insiders · 316 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

John C Martin

Director

—

$116.41M (47) scheduled

−$116.41M

2,887,225

0.2328%

$493.90M

−7.8%

Daniel Patrick O'Day

Chairman & CEO

—

$63.37M (43) scheduled

−$63.37M

551,683

0.0445%

$94.37M

—

Andrew D Dickinson

Chief Financial Officer

—

$62.65M (32) scheduled

−$62.65M

161,096

0.0130%

$27.56M

—

Johanna Mercier

Chief Comm & Corp Aff Officer

—

$32.38M (43) scheduled

−$32.38M

113,684

0.0092%

$19.45M

—

Gregg H Alton

Chief Patient Officer

—

$25.29M (30) scheduled

−$25.29M

58,046

0.0047%

$9.93M

−60.6%

Merdad Parsey

Chief Medical Officer

—

$22.24M (19) scheduled

−$22.24M

82,850

0.0067%

$14.17M

—

John F Milligan

President and CEO

—

$16.03M (1) scheduled

−$16.03M

1,574,306

0.1270%

$269.31M

+48.7%

James R Meyers

EVP Worldwide Commercial Ops

—

$13.02M (4) scheduled

−$13.02M

137,476

0.0111%

$23.52M

+7.5%

Brett A Pletcher

EVP,Corp Affairs & Gen Counsel

—

$9.34M (24) scheduled

−$9.34M

33,426

0.0027%

$5.72M

+373.7%

Gayle E Wilson

Director

—

$8.84M (4) scheduled

−$8.84M

129,052

0.0104%

$22.08M

+22.5%

John W Madigan

Director

—

$7.86M (1) scheduled

−$7.86M

18,548

0.0015%

$3.17M

+10.7%

John Francis Cogan

Director

—

$7.52M (28) scheduled

−$7.52M

54,860

0.0044%

$9.38M

+19.8%

Deborah H Telman

EVP, Corporate Affairs & GC

—

$6.59M (3) scheduled

−$6.59M

43,676

0.0035%

$7.47M

+6,538%

Robin L Washington

EVP, CFO

—

$4.81M (3) scheduled

−$4.81M

138,943

0.0112%

$23.77M

+6.1%

Diane E. Wilfong

Interim Corp Controller & CAO

—

$3.79M (4) scheduled

−$3.79M

46,259

0.0037%

$7.91M

+137.5%

Olsen Per Wold

Director

—

$3.19M (3) scheduled

−$3.19M

102,060

0.0082%

$17.46M

+11.5%

Jeffrey Bluestone

Director

—

$3.14M (9) scheduled

−$3.14M

10,066

0.0008%

$1.72M

—

Anthony Welters

Director

—

$2.68M (4) scheduled

−$2.68M

12,894

0.0010%

$2.21M

—

Richard James Whitley

Director

—

$2.55M (3) scheduled

−$2.55M

33,058

0.0027%

$5.65M

+31.5%

Kelly A. Kramer

Director

—

$713.19K (2) scheduled

−$713.19K

1,339

0.0001%

$229.05K

—

Javier Rodriguez

Director

—

$14.27K (1)

−$14.27K

13,364

0.0011%

$2.29M

+6,971%

Norbert W Bischofberger

EVP, R&D and CSO

—

—

—

2,337,402

0.1885%

$399.84M

−0.1%

Kevin E Lofton

Director

—

—

—

101,095

0.0082%

$17.29M

+174.9%

Sandra Patterson

SVP, Controllership

—

—

—

39,453

0.0032%

$6.75M

+59.4%

John G McHutchison

Chief Scientific Off/HeadR&D

—

—

—

37,828

0.0031%

$6.47M

+65.1%

Jacqueline K Barton

Director

—

—

—

27,202

0.0022%

$4.65M

+105.1%

Kevin Young

Chief Operating Officer

—

—

—

25,612

0.0021%

$4.38M

+1,531%

Dietmar Berger

Chief Medical Officer

—

—

—

19,522

0.0016%

$3.34M

—

Harish Manwani

Director

—

—

—

15,015

0.0012%

$2.57M

—

Nicholas G Moore

Director

—

—

—

12,233

0.0010%

$2.09M

−20.0%

Wettan Keeley M Cain

EVP Gen Counsel, Legal & Comp

—

—

—

8,759

0.0007%

$1.50M

+122.1%

Laura Hamill

EVP, Worldwide Commercial Ops

—

—

—

6,340

0.0005%

$1.08M

—

Sandra Horning

Director

—

—

—

6,293

0.0005%

$1.08M

—

Ted W Love

Director

—

—

—

5,484

0.0004%

$938.11K

—

Erin Burkhart

SVP, Controllership

—

—

—

1,455

0.0001%

$248.90K

—